NCT01687582已完成不适用
Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
Cliniques universitaires Saint-Luc- Université Catholique de Louvain1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Improvement of PASI score
研究概览
简要总结
The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
详细描述
The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments.
排除标准
- •Type 1 diabetes
- •Secondary diabetes
- •Liver, renal or pancreatic disease
- •Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents
研究组 & 干预措施
GLP-1 analog
Experimental
Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
干预措施: GLP-1 analog (Drug)
结局指标
主要结局
Improvement of PASI score
时间窗: 4 to 6 months
次要结局
- Evolution of BMI(4 to 6 months)
- Evolution of immunological data(4 to 6 months)
- Evolution of BMI (body mass index)(4 to 6 months)
- Evolution of histopathological data(4 to 6 months)
- Evolution of glycaemic control(4 to 6 months)
- Evolution of routine laboratory measures(4 to 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesType 2 DiabetesNCT01744236Amsterdam UMC, location VUmc70
已完成
4 期
Effects of Liraglutide in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT03466021Claus Bogh Juhl40
已完成
2 期
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?Alcohol AbuseAlcohol AddictionAlcohol Use DisorderAlcohol DependenceNCT05895643Psychiatric Centre Rigshospitalet108
已完成
2 期
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)Maturity-onset Diabetes of the YoungNCT01610934University Hospital, Gentofte, Copenhagen15
Unknown
2 期
Evaluating Liraglutide in Alzheimer's DiseaseAlzheimer's DiseaseNCT01843075Imperial College London204